|1.||Miura, M: 5 articles (01/2005 - 04/2001)|
|2.||Micca, P L: 5 articles (01/2005 - 04/2001)|
|3.||Coderre, J A: 4 articles (01/2005 - 04/2001)|
|4.||Morris, G M: 4 articles (01/2005 - 04/2001)|
|5.||Nawrocky, M M: 3 articles (01/2005 - 04/2001)|
|6.||Slatkin, D N: 3 articles (07/2004 - 04/2001)|
|7.||Miura, Michiko: 2 articles (08/2013 - 03/2003)|
|8.||Micca, Peggy L: 2 articles (08/2013 - 03/2003)|
|9.||Hopewell, J W: 2 articles (01/2005 - 03/2003)|
|10.||Hoch, D A: 2 articles (04/2001 - 04/2001)|
|1.||Mouth Neoplasms (Oral Cancer)
08/01/2013 - "ZnTCPH serves as a useful fluorescent experimental surrogate for CuTCPH to delineate its macroscopic and microscopic distributions in organs and tumors."
08/01/2013 - "ZnTCPH-injected, but not CuTCPH-injected mice bearing subcutaneous tumors showed fluorescence from liver, spleen and tumors. "
08/01/2013 - "ZnTCPH and CuTCPH were synthesized, then injected intraperitoneally (ip) into tumor-bearing mice. "
03/01/2003 - "CuTCPH is a novel, non-toxic compound that may be advantageous in terms of selective and absolute delivery of boron to tumor tissues. "
04/01/2001 - "When 190 mg CuTCPH/kg body weight was given to the rats by i.v. infusion, median tissue boron concentrations (microg/g) 3 days after the end of infusion were: 64 in subcutaneous tumor, 13 in intracranial tumor, 1 in blood and 3 in brain. "
|3.||Body Weight (Weight, Body)
03/01/2003 - "We administered CuTCPH intraperitoneally (i.p.) as a single dose of 32 microg/g body weight (b.w.) (10 microg B/g b.w.) or as four doses of 32 microg/g b.w. "
04/01/2001 - "injection of a total of 190 mg CuTCPH/kg body weight were: 251 in U373, 33 in U87, <0.6 in blood and <0.5 in brain. "
04/01/2001 - "When 450 mg CuTCPH/kg body weight was given to the rats by serial i.p. "
01/01/2005 - "CuTCPH was administered by intravenous infusion, at a dose of 200 mg/kg body weight, over a 48-h period. "
03/01/2003 - "CuTCPH was administered by intravenous infusion at a dose of 200 mg x kg(-1) body weight, over 48 h. "
04/01/2001 - "CuTCPH biodistribution was also studied in xenografts of the human malignant gliomas U87 and U373, and of the murine EMT-6 mammary carcinoma and the rat 9LGS, each grown subcutaneously in mice with severe combined immunodeficiency (SCIDs). "
04/01/2001 - "The biodistributions of carborane-containing copper porphyrins, CuTCP and CuTCPH, have been studied previously in mice bearing subcutaneously implanted mammary carcinomas. "
04/01/2001 - "In mice bearing implanted EMT-6 mammary carcinomas, boron uptake using a single injection of either p-boronophenylalanine (BPA) or mercaptoundecahydrododecaborane (BSH) was compared with either a single injection or multiple injections of the carboranylporphyrin CuTCPH. "
|5.||Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
|1.||Boron Neutron Capture Therapy
|3.||Heterologous Transplantation (Xenotransplantation)